Digest Network Come funziona
Network
/
Società
Su
Non verificato

Summit Therapeutics Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

39 comunicati stampa

Guarda tutti i comunicati
30/06/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Mercato del lavoro
Industria
Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors
Fonte
Summit Therapeutics Inc.
Emittente
Business Wire
1.00
0
06/06/2025
Mercato azionario
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Medicina - Varie
Sanità
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fonte
Summit Therapeutics Inc.
Emittente
Business Wire
1.00
0
05/06/2025
Eventi
Web e Social Network
Biotecnologia
Farmaceutica
Salute
Oncologia
Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
Fonte
Summit Therapeutics Inc.
Emittente
Business Wire
1.00
0
30/05/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer after EGFR TKI Therapy in Global Study
Fonte
Summit Therapeutics Inc.
Emittente
Business Wire
1.00
0
16/05/2025
Mercato azionario
Finanza
Scienza
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
Oncologia
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fonte
Summit Therapeutics Inc.
Emittente
Business Wire
1.00
0
01/05/2025
Web e Social Network
Telefonia e Varie
Mercato azionario
Biotecnologia
Farmaceutica
Salute
Oncologia
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025
Fonte
Summit Therapeutics Inc.
Emittente
Business Wire
1.00
0
25/04/2025
Industria
Scienza
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Medicina - Varie
Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in China
Fonte
Summit Therapeutics Inc.
Emittente
Business Wire
1.00
0
24/04/2025
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Biotecnologia
Farmaceutica
Salute
Oncologia
Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025
Fonte
Summit Therapeutics Inc.
Emittente
Business Wire
1.00
0
23/04/2025
Industria
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Medicina - Varie
Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China
Fonte
Summit Therapeutics Inc.
Emittente
Business Wire
1.00
0
04/04/2025
Mercato azionario
Finanza
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Medicina - Varie
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fonte
Summit Therapeutics Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0